newest glp 1 medication New GLP-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity Understanding GLP-1 medications

The early stages prioritize tolerability

[97] observed a potential association between semaglutide and NAION, with incidence rates of 4.28 and 7.64 per 1,000 person-years in patients with T2DM and those who were overweight or obese, respectively, over 36 months

Dose Sensitivity: Achieving significant, sustained weight loss while staying on the lowest possible "starter" doses, never needing to titrate up to the maximum manufacturer-recommended levels. The Genetic "Sweet Tooth" Discovery For years, doctors wondered why two people of the same age and weight could have such different reactions to the same dose

This very short action limited the initial enthusiasm for the possible usefulness of incretins for the treatment of T2DM, and in turn stimulated the development of both GLP1 agonists resistant to DPP-4, with a longer half-life and of DPP-4 inhibitors that prolong the half-life of native incretins